Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.19), $0.07 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.07 million.

Ended Q2 2018 with $25.3 million in cash and cash equivalents.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.